Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?

Not Applicable

Completed

• Conditions: Glaucoma
• Interventions: Procedure: Blood Sample

• Registration Number: NCT00312403
• Lead Sponsor: Medical University of Vienna

Brief Summary

Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes. MMPs are also important disease modulating factors, such as cancer, cardiovascular disease, rheumatoid arthritis or macular degeneration. Functional genetic variants have been described to fine-tune MMP activities at the gene transcriptional level and have been associated with increased genetic risk of e.g. arteriosclerosis or cancer. MMPs are also assumed to play a major role in the remodeling of the extracellular matrix (ECM) in the optic nerve head during glaucomatous optic neuropathy. MMP-1, MMP-3 and MMP-9 have been shown to be up-regulated in a variety of animal models of glaucoma. Here, we study three promoter SNPs within the genes encoding three members of the MMP family. By assessing the prevalence of genetic variants associated with either increased/decreased enzyme activity, we will (i) estimate their contribution to the genetic risk of developing primary open angle glaucoma (POAG) and (ii) investigate the potential role of MMPs in the functional pathology of POAG.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Study First Submitted: 2006-04-06
• Study First Submitted QC: 2006-04-06
• Study First Posted: 2006-04-10
• Primary Completion: 2009-11
• Study Completion: 2009-12
• Status Verified: 2010-01
• Last Update Submitted: 2010-01-14
• Last Update Posted: 2010-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Men and women older than 39 years
• Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
• Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion Criteria

• Exfoliation glaucoma, pigmentary glaucoma
• History of acute angle closure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Blood Sample	Patients with primary open angle glaucoma
2	Blood Sample	Age- and sex-matched control subjects

Primary Outcome Measures

Name	Time	Method
Genotyping results and putatively associated odds with occurence of primary open angle glaucoma.	15 minutes

Trial Locations

Locations (1)

Department of Clinical Pharmacology; 🇦🇹 Vienna, Austria